You just read:

Initial Data from Ongoing Expansion Study of MGCD265 Show Preliminary Evidence of Clinical Efficacy in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients with MET Gene Alterations

News provided by

Mirati Therapeutics, Inc.

May 30, 2015, 09:16 ET